Plain-English translation of NCT04561206 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two immunotherapy medications— and —work well together to treat Hodgkin lymphoma that has come back or didn't respond to initial treatment. The study focuses on patients who are not candidates for stem cell transplant, and researchers want to see how long the benefits last and whether the treatment is safe.
Hodgkin lymphoma that returns or resists initial treatment is serious and difficult to manage. This medication combination may offer a gentler alternative to stem cell transplant for some patients, and researchers want to understand how effective and durable this approach is.
You likely qualify if…
You likely don't qualify if…
You would receive two medications by IV infusion on day 1 of each treatment cycle, with each cycle lasting 21 days. Treatment would continue for up to 16 cycles (about 11 months) unless your disease worsens or you experience unacceptable side effects. After treatment ends, you would return for follow-up appointments at 30 days, then at 6, 12, 18, 24, 36, 48, and 60 months to check how well the treatment is working and monitor for any long-term effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States